Caris Life Sciences, Inc. 8-K

What Happened

• On April 1, 2026, Caris Life Sciences, Inc. announced a new Financing Agreement (the “New Credit Agreement”) providing senior secured credit facilities including a $400 million initial term loan funded on the closing date, a committed delayed draw term loan facility of up to $300 million (available through August 2027), and an uncommitted incremental facility up to $500 million. Lenders include funds managed by Blue Owl Capital and Blackstone, with Blue Owl Capital Corporation acting as administrative agent. The loans are guaranteed by certain subsidiaries and secured by substantially all tangible and intangible personal property and equity of direct subsidiaries.
• Proceeds from the initial term loan were used to repay and terminate the company’s prior credit agreement (dated January 18, 2023). The company also reported (Item 2.03) that the New Credit Agreement creates a direct financial obligation.

Key Details

• Initial Term Facility: $400,000,000 funded on April 1, 2026; matures April 2031.
• Delayed Draw Facility: up to $300,000,000 available through August 2027; may be used solely for Permitted Acquisitions.
• Interest margins: +5.00% over Term SOFR or +4.00% over Base Rate for initial/delayed term loans; interest periods selectable (1, 3, 6 months, etc.).
• Covenants/security: customary affirmative/negative covenants; minimum qualified cash requirement of $50 million (tested quarterly); first‑priority security interest in substantially all personal property and pledges of subsidiary equity.
• Other: contains customary events of default (including change of control) and prepayment provisions (including possible prepayment premium). Previous credit agreement and related guarantees and liens were terminated.

Why It Matters

• This agreement materially affects Caris’s capital structure and liquidity: it provides immediate funding ($400M) and acquisition capacity (up to $300M through the delayed draw) while replacing the prior credit facility. Investors should note the 2031 maturity (longer‑term runway), the secured nature of the debt, the quarterly $50M minimum cash covenant, and the relatively high interest margin, which will influence interest expense and financial flexibility. The delayed draw’s restriction to Permitted Acquisitions ties additional borrowing to acquisition activity rather than general corporate use.